Why the study?
Does selegiline improve cardiac sympathetic terminal function and beta-adrenergic responsiveness in a rabbit model of pacing-induced heart failure?
Does selegiline improve cardiac sympathetic terminal function and beta-adrenergic responsiveness in a rabbit model of pacing-induced heart failure?
Answers are grounded in this paper and cite their sources.
In a rabbit model of pacing-induced cardiomyopathy, selegiline demonstrated sympatholytic and neuroprotective effects, improving cardiac function and baroreflex sensitivity.
Selegiline is a centrally acting sympatholytic agent with neuroprotective properties. It also has been shown to promote sympathetic reinnervation after sympathectomy. These actions of selegiline may be beneficial in heart failure that is characterized by increased sympathetic nervous activity and functional sympathetic denervation. Twenty-seven rabbits with rapid cardiac pacing (360 beats/min, 8 wk) and twenty-three rabbits without pacing were randomly assigned to receive selegiline (1 mg/day, 8 wk) or placebo. Rapid pacing increased plasma norepinephrine (NE) and decreased left ventricular fractional shortening, baroreflex sensitivity, cardiac sympathetic nerve terminal profiles, cardiac NE uptake activity, and myocardial beta-adrenoceptor density. Selegiline administration to animals with rapid ventricular pacing attenuated the increase in plasma NE and decreases in fractional shortening, baroreflex sensitivity, sympathetic nerve profiles, NE uptake activity and beta-adrenoceptor density. Thus selegiline appears to exert a sympatholytic and cardiac neuroprotective effect in pacing-induced cardiomyopathy. The effects are potentially beneficial because selegiline not only improves cardiac function but also increases baroreflex sensitivity in heart failure.
No takes yet. Share an insight, caveat, or question.
Shite et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: